Results 101 to 110 of about 276,787 (297)

Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder

British Journal of Clinical Pharmacology, EarlyView.
Aims Insomnia is a common sleep disorder, affecting up to 20% of the world population and adversely impacting productivity, health, and overall well‐being. Although pharmacologic options exist to treat insomnia, the health‐related quality of life for patients who are prescribed hypnotics is no higher than for those who are not, revealing a significant ...
Garth T. Whiteside, Ellie He, Manjunath S. Shet, Mingyan Zhou, Maha Ahmad, Stephen C. Harris   +5 more
wiley   +1 more source

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance Despite available medications for depression, currently approved antidepressants take months to exert therapeutic effects, and ∼30% of patients remain treatment resistant.
P. Zanos, Jaclyn N. Highland, Brent W. Stewart, Polymnia Georgiou, Carleigh E. Jenne, Jacqueline Lovett, Patrick J. Morris, Craig J. Thomas, R. Moaddel, C. Zarate, T. Gould   +10 more
semanticscholar   +1 more source

Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de

British Journal of Clinical Pharmacology, EarlyView.
Aim Drugs with anticholinergic effects are often considered as potentially inappropriate medications, especially for older patients, and deprescribing such drugs may improve cognitive function. The aim was to investigate the effectiveness of counselling on drug risks as part of a multimodal intervention to prevent cognitive decline. Methods The AgeWell.
Laura K. Lepenies, Hanna M. Seidling, Alexander Pabst, Melanie Luppa, Juliane Döhring, Martin Williamson, Thomas Frese, Jochen Gensichen, Wolfgang Hoffmann, Hanna Kaduszkiewicz, Hans‐Helmut König, Jochen René Thyrian, Birgitt Wiese, Steffi G. Riedel‐Heller, David Czock   +14 more
wiley   +1 more source

Clinical effectiveness and treatment satisfaction between two triple‐therapy regimens in treating neuropathic pain: A real‐world data

Ibrain, EarlyView., 2023
This study compared the clinical effectiveness and treatment satisfaction of Pregabalin and Gabapentin triple therapy for neuropathic pain in a real‐world setting. The primary outcome measured the reduction in mean Self‐Administered Leeds Assessment of Neuropathic Symptoms and Signs pain score value from baseline to 12 weeks posttreatment.
Nithya Raju, Samyuktha Villavan, Saranya Ravi, Roja Murugesan, Panneerselvam Theivendren, Vennila Jaganathan, Redlin Jani Rajan, Krupanidhi Karunanithi   +7 more
wiley   +1 more source

Ketamine in the Treatment of Depression

Journal of Education, Health and Sport
Introduction Depression is one of the most common mental illnesses. Over the course of a lifetime, several percent of the adult population suffers from depression. There are many treatments for depression like pharmacotherapy and psychotherapy.
Urszula Agnieszka Kaczmarska, Michał Jakub Cioch, Julia Nowak, Aleksandra Woźniak, Kamil Hermanowicz, Agnieszka Najdek , Daria Oleksy , Dawid Komada, Katarzyna Doman , Marcin Mycyk   +9 more
doaj   +1 more source

Impact of Social Status and Antidepressant Treatment on Neurogenesis in the Baboon Hippocampus [PDF]

, 2014
Melody V. Wu, Jul Lea Shamy, Gillinder Bedi, Chien-Wen Jean Choi, Melanie M. Wall, Victoria Arango, Maura Boldrini, Richard W. Foltin, René Hen   +8 more
openalex   +1 more source

Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database

British Journal of Clinical Pharmacology, EarlyView.
Aims Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life‐threatening psychiatric events in some individuals.
Amy G. McNeilage, Ali Gholamrezaei, Bridin Murnion, Suzanne Nielsen, Claire E. Ashton‐James   +4 more
wiley   +1 more source

Chronic Fluoxetine Treatment Induces Maturation-Compatible Changes in the Dendritic Arbor and in Synaptic Responses in the Auditory Cortex

Frontiers in Pharmacology, 2019
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) used to treat mood and anxiety disorders. Chronic treatment with this antidepressant drug is thought to favor functional recovery by promoting structural and molecular changes in several ...
Estibaliz Ampuero, Mauricio Cerda, Steffen Härtel, Steffen Härtel, Francisco Javier Rubio, Solange Massa, Paula Cubillos, Lorena Abarzúa-Catalán, Rodrigo Sandoval, Albert M. Galaburda, Ursula Wyneken   +10 more
doaj   +1 more source

Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study

Molecular Psychiatry, 2021
N. Hoertel, M. Sánchez-Rico, R. Vernet, N. Beeker, A. Jannot, A. Neuraz, E. Salamanca, N. Paris, C. Daniel, Alexandre Gramfort, G. Lemaître, M. Bernaux, A. Bellamine, C. Lemogne, G. Airagnes, A. Burgun, F. Limosin   +16 more
semanticscholar   +1 more source

Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine

Proceedings of the National Academy of Sciences of the United States of America, 2018
Significance A metabolite of ketamine, (2R,6R)-hydroxynorketamine [(2R,6R)-HNK], produces rapid and sustained antidepressant effects in animal models but without the side effects of ketamine.
K. Fukumoto, M. Fogaça, Rong‐jian Liu, C. Duman, Taro Kato, Xiao-Yuan Li, R. Duman   +6 more
semanticscholar   +1 more source